（二）独立董事任职董事会专门委员会的情况 嘉兴中润光学科技股份有限公司 2023 年度独立董事履职情况报告（周红锵） 作为嘉兴中润光学科技股份有限公司（以下简称"公司"）的独立董事，2023 年度本人严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司独立董事管理办法》《上海证券交易所科创板股票上市规则》等法律法规及 《公司章程》《独立董事工作制度》等规定，勤勉尽责、恪尽职守，积极履行独 立董事职责，积极参加公司股东大会、董事会及各专门委员会会议，充分发挥独 立董事的作用，推动公司高质量发展，切实维护了公司和全体股东的合法权益， 积极促进公司规范运作和治理水平的提升。现将2023年度履行独立董事职责的情 况报告如下： 一、独立董事基本情况 （一）现任独立董事基本情况 周红锵，中国国籍，无境外永久居留权，1974年5月出生，法学专业本科学 历，获得法学硕士学位，副教授。1997年7月至今任杭州师范大学助教、讲师、 副教授。2020年10月至今任中润光学独立董事。目前还担任浙江万得凯流体设备 科技股份有限公司（股票代码：301309）、浙江米居梦家纺股份有限公司（未上 市）、浙江远景体育用品股份有 ...

证券代码：688307 证券简称：中润光学 公告编号：2024-013 嘉兴中润光学科技股份有限公司 关于使用部分暂时闲置的募集资金及自有资金 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉兴中润光学科技股份有限公司（以下简称"公司"）于2024年4月26日分别 召开了第二届董事会第二次会议和第二届监事会第二次会议，分别审议通过了《关 于使用部分暂时闲置的募集资金及自有资金进行现金管理的议案》。根据决议， 在不影响公司募投项目正常实施进度的情况下，公司及子公司计划使用不超过人 民币3亿元（含本数）部分暂时闲置的募集资金及不超过人民币3亿元（含本数） 的自有资金进行现金管理，用于购买安全性高、流动性好、有保本约定的投资产 品（包括但不限于保本型理财产品、结构性存款、通知存款、定期存款、大额存 单等），使用期限自2023年度股东大会审议通过之日起12个月，在上述额度内的 资金可在投资期限内滚动使用，其中与募集资金相关的现金管理资金期满后归还 至公司募集资金专项账户。 在授权额度范围内，董事会提请股东大会 ...

Financial Performance - In 2023, the company's operating revenue was CNY 378.85 million, a decrease of 6.23% compared to 2022[22]. - The net profit attributable to shareholders was CNY 36.33 million, down 11.64% year-on-year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 30.66 million, a decrease of 6.71% compared to the previous year[22]. - The net cash flow from operating activities was CNY 105.47 million, an increase of 195.12% year-on-year[22]. - Total assets at the end of 2023 reached CNY 1,017.54 million, a year-on-year increase of 75.31%[23]. - The net assets attributable to shareholders at the end of 2023 were CNY 838.30 million, up 128.20% from the previous year[23]. - Basic and diluted earnings per share decreased by 30.65% to CNY 0.43[24]. - The decline in revenue and net profit was attributed to macroeconomic fluctuations and short-term demand volatility from downstream customers[23]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 3.0 per 10 shares, totaling RMB 26.4 million, which represents 72.67% of the net profit attributable to shareholders for 2023[6]. - The board of directors has approved the profit distribution plan, pending approval from the annual general meeting[6]. - The total share capital of the company is 88 million shares[6]. Research and Development - The proportion of R&D investment to operating revenue increased by 0.62 percentage points to 10.69%[23]. - The company invested 4,051.72 million yuan in R&D, accounting for 10.69% of operating revenue[39]. - A total of 21 patents were applied for during the reporting period, including 17 invention patents, with 10 patents granted[39]. - The company has increased R&D efforts in glass-plastic hybrid lenses to enhance its product offerings in the smart monitoring and perception sector[35]. - The company aims to leverage its industry-leading advantages in ultra-high-definition and long-focus zoom products within the digital security field[35]. Market and Product Development - The company is focusing on the development of optical lenses, which are critical components in various advanced technologies, including AI and smart cities[34]. - The company aims to continue penetrating high-difficulty and high-value markets by developing competitive new products in response to the growing demands of emerging industries[57]. - The company has made breakthroughs in 8K ultra-high-definition optical lens design and ultra-short throw projection technology, launching key products like 8K full-frame cinema lenses[57]. - The company is expanding its product line through innovative optical system designs, including glass-plastic hybrid systems and ultra-high-definition AI recognition systems, enhancing its competitive edge[56]. Risk Management and Governance - The company has established a risk management mechanism to identify, assess, and respond to potential risks, enhancing internal control effectiveness[194]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures for providing guarantees[8]. - The company has not faced any issues with more than half of the directors being unable to guarantee the authenticity of the annual report[8]. - The company has established a comprehensive internal audit system to monitor and evaluate the effectiveness of internal controls, ensuring compliance and operational efficiency[194]. Customer and Market Concentration - The top five customers accounted for 52.20% of total revenue, a decrease of 7.50 percentage points from the previous year, but still indicating a high customer concentration risk[88]. - The company is expanding into new markets such as AIoT, but faces uncertainties in market development and technology application[87]. Operational Efficiency - Operating cash flow for the year was CNY 105.47 million, a significant increase of 195.12% compared to the previous year, indicating improved cash generation capabilities[100]. - The company’s sales expenses increased by 34.99% to CNY 10.27 million, while management expenses rose by 23.86% to CNY 52.54 million, reflecting higher operational costs[100]. - The gross profit margin for the optical lens manufacturing sector increased by 0.60 percentage points to 33.80% despite a 5.31% decrease in revenue[103]. Corporate Governance - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making or operations[149]. - The company adheres to strict information disclosure practices, ensuring transparency and protecting the interests of all shareholders[150]. - The company has a structured approach to investor relations, actively seeking feedback from shareholders[151]. - The company’s governance practices align with the requirements of the Company Law and Securities Law[152]. Future Outlook - The company is optimistic about future growth, projecting a revenue increase of 15% for the next fiscal year[158]. - New product development is underway, focusing on innovative technologies that are expected to launch in Q2 2024[158]. - The company plans to expand its market presence in Asia, targeting a 20% increase in market share by the end of 2024[158].

证券代码：688307 证券简称：中润光学 公告编号：2024-017 嘉兴中润光学科技股份有限公司 第二届董事会第二次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会召开情况 嘉兴中润光学科技股份有限公司（以下简称"公司"）于 2024 年 4 月 16 日，向全体董事发出了关于召开公司第二届董事会第二次会议的通知。该会议于 2024 年 4 月 26 日以现场方式召开，应出席会议董事 7 名，实际出席会议董事 7 名。本次会议由董事长张平华先生主持，会议的召集和召开符合法律、行政法规、 部门规章和《嘉兴中润光学科技股份有限公司章程》（以下简称"《公司章程》"） 《嘉兴中润光学科技股份有限公司董事会议事规则》（以下简称"《董事会议事 规则》"）的有关规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于 2023 年度董事会工作报告的议案》 2023 年度，公司董事会严格按照法律法规和《公司章程》及《董事会议事 规则》等相关规定，切实履行董事会职责，严格执行股东大会决议，持续完善公 司治理， ...

嘉兴中润光学科技股份有限公司（以下简称"公司"）聘请天健会计师事务所 （特殊普通合伙）（以下简称"天健所"）作为公司 2023 年度财务报告审计机构和 内部控制审计机构。根据《中华人民共和国公司法》《中华人民共和国证券法》《国 有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律法规的要 求，公司董事会审计委员会对天健所 2023 年度审计履职评估及履行监督职责情况 汇报如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 天健所成立于成立于 2011 年 7 月 18 日，注册地址为杭州市，首席合伙人为 王国海先生。是由一批资深注册会计师创办的首批具有 A+H 股企业审计资质的全 国性大型会计审计服务机构。 证券代码：688307 证券简称：中润光学 嘉兴中润光学科技股份有限公司 2023 年度审计委员会监督会计师事务所履职情况报告 公司董事会审计委员会对天健的资质进行了严格审核。2023 年 3 月 30 日， 第一届审计委员会第九次审议通过了《关于 2023 年度续聘会计师事务所的议案》， 审 ...

证券代码：688307 证券简称：中润光 学 嘉兴中润光学科技股份有限公司 2023 年度审计委员会履职情况报告 根据中国证监会《上市公司治理准则》《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》《上海证券交易所科创板股票上市规则》等法 律、法规、规范性文件、《嘉兴中润光学科技股份有限公司章程》及《嘉兴中润 光学科技股份有限公司审计委员会工作细则》的有关规定，嘉兴中润光学科技股 份有限公司(以下简称"公司")董事会审计委员会恪尽职守，勤勉尽责，认真履 行了审计监督职责。现就 2023 年度公司董事会审计委员会履职情况报告如下: 一、审计委员会基本情况 2020 年 10 月 17 日公司召开第一届董事会第一次会议聘任朱朝晖女士、周 红锵女士、张明锋先生担任公司第一届董事会审计委员会委员，其中朱朝晖女士 为主任委员。2023 年 11 月 14 日公司召开第二届董事会第一次会议聘任朱朝晖 女士、周红锵女士、陆高飞先生担任公司第二届董事会审计委员会委员，其中独 立董事占比为三分之二，并由具备会计专业资格和经验的朱朝晖女士担任主任委 员。 2023 年度，审计委员会委员凭借丰富的行业经验及专业审 ...

国信证券股份有限公司 关于嘉兴中润光学科技股份有限公司 使用部分暂时闲置的募集资金及自有资金进行现金管理的核查意见 国信证券股份有限公司（以下简称"国信证券"或"保荐机构"）作为嘉兴 中润光学科技股份有限公司（以下简称"中润光学"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则（2023 年 8 月修订）》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作（2023 年 12 月修订）》 等有关规定，对公司使用部分暂时闲置的募集资金及自有资金进行现金管理的事 项进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2022 年 12 月 5 日签发的《关于同意嘉兴中 润光学科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕3064 号），公司获准向社会公开发行人民币普通股（A 股）股票 2,200 万股，每股面值 1 元，每股发行价格为人民币 23.88 元，募集资金总额为人民币 52 ...

证券代码：688307 证券简称：中润光学 公告编号：2024-015 嘉兴中润光学科技股份有限公司 关于 2024 年度申请综合授信额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 嘉兴中润光学科技股份有限公司（以下简称"公司"）（含合并报表范围 内的子公司）拟向银行等金融机构申请综合授信额度合计不超过人民币 3.5 亿元。 本事项尚需提交公司 2023 年度股东大会审议。 嘉兴中润光学科技股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日召开第二届董事第二次会议、第二届监事会第二次会议，分别审议通过了《关 于 2024 年度申请综合授信额度的议案》。现将相关事项公告如下： 为满足生产经营及业务发展的需要，公司（含合并报表范围内的子公司，下 同）2024 年度拟向银行等金融机构申请总额不超过 3.5 亿元人民币的综合授信额 度。授信额度有效期自审议本议案的年度股东大会决议通过之日起至下一年度审 议年度授信额度的股东大会召开之日止。授信业务品种、授信额度以及授信银行 以实际审批结果 ...

国信证券股份有限公司 关于嘉兴中润光学科技股份有限公司 使用部分超募资金永久补充流动资金的核查意见 国信证券股份有限公司（以下简称"国信证券"或"保荐机构"）作为嘉兴 中润光学科技股份有限公司（以下简称"公司"或"中润光学"）首次公开发行 股票并在科创板上市的持续督导保荐机构，根据《证券发行上市保荐业务管理办 法》《上海证券交易所科创板股票上市规则》《上市公司监管指引第 2 号——上市 公司募集资金管理和使用的监管要求》《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》等有关规定，对公司使用部分超募资金永久补充流 动资金的事项进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2022 年 12 月 5 日签发的《关于同意嘉兴中 润光学科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕3064 号），公司获准向社会公开发行人民币普通股（A 股）股票 2,200 万股，每股面值 1 元，每股发行价格为人民币 23.88 元，募集资金总额为人民币 525,360,000.00 元，扣除发行费用人民币 79,189,860.99 元，实际募集资金净额为 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥79,483,812.18, representing an increase of 18.04% compared to the same period last year[4] - The net profit attributable to shareholders was ¥11,087,867.94, marking a turnaround from a loss of ¥947,400 in the previous year[8] - Basic and diluted earnings per share were both ¥0.13, compared to a loss of ¥0.01 per share in the same quarter last year[9] - The company reported a significant improvement in net profit after deducting non-recurring gains and losses, reaching ¥8,698,828.20, compared to a loss of ¥1,182,200 in the same period last year[8] - Operating profit for Q1 2024 was ¥11,508,535.57, a significant recovery from a loss of ¥448,608.34 in Q1 2023[20] - Net profit for Q1 2024 was ¥11,202,244.68, compared to a net loss of ¥708,725.43 in the same period last year[21] Cash Flow - The net cash flow from operating activities was -¥1,211,664.14, a significant improvement of 93.20% year-over-year[8] - The company reported a net cash outflow from operating activities of ¥1,211,664.14, an improvement from a net outflow of ¥17,831,345.30 in Q1 2023[23] - The company generated cash inflows from operating activities totaling ¥96,680,201.72, up from ¥79,576,521.33 in the previous year[23] - The net cash flow from investing activities was -$32.51 million, compared to -$21.22 million in the previous period, indicating an increase in cash outflow for investments[24] - The total cash inflow from financing activities was $490.32 million, primarily from equity investments and loans received[24] - The net cash flow from financing activities was -$0.76 million, a significant decrease from $431.49 million in the previous period, reflecting reduced financing activities[24] - The company experienced a net decrease in cash and cash equivalents of -$34.42 million during the quarter, contrasting with an increase of $392.19 million in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,015,908,245.78, a slight decrease of 0.16% from the end of the previous year[5] - Current assets totaled RMB 664,339,982.73, down from RMB 693,603,350.02 at the end of 2023, primarily due to a decrease in cash and cash equivalents[15] - Total liabilities decreased to ¥162,656,473.80 from ¥176,031,613.75 year-over-year[20] - Current liabilities decreased to RMB 114,417,398.95 from RMB 127,142,498.78, showing improved liquidity management[16] - The equity attributable to shareholders increased by 1.41% to ¥850,158,597.87 compared to the end of the previous year[5] - Shareholders' equity increased to ¥850,158,597.87 from ¥838,302,518.17 in the previous year[20] Research and Development - The total R&D investment was ¥9,478,770.98, accounting for 11.93% of operating revenue, a decrease of 1.95 percentage points from the previous year[5] - Research and development expenses remained stable at ¥9,478,770.98, compared to ¥9,348,062.73 in Q1 2023[20] Government Support - The company received government subsidies amounting to ¥2,803,476.83, contributing to the profit increase[8] Shareholder Relations and Strategy - The company has no significant changes in shareholder relationships or actions during the reporting period[13] - There were no significant new strategies or product developments announced during the earnings call[13] Accounting Practices - The company did not apply new accounting standards or interpretations for the year 2024, indicating stability in financial reporting practices[25]